<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cardiovascular complications are the most important cause of <z:hpo ids='HP_0011420'>death</z:hpo> in patients on dialysis with <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Antibodies reacting with β-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I seem to play a pathogenic role in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and <z:hpo ids='HP_0001297'>stroke</z:hpo> and are involved in the origin of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Here we evaluated the presence of anticardiolipin and anti-β-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies together with other vascular risk factors and their relationship with mortality and <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> in a cohort of 124 hemodialysis patients prospectively followed for 2 years </plain></SENT>
<SENT sid="3" pm="."><plain>Of these, 41 patients were significantly positive for IgA anti-β-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I, and the remaining had <z:mpath ids='MPATH_458'>normal</z:mpath> values </plain></SENT>
<SENT sid="4" pm="."><plain>At 24 months, overall and cardiovascular mortality and thrombotic events were <z:hpo ids='HP_0000001'>all</z:hpo> significantly higher in patients with high anti-β-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariate analysis using Cox regression modeling found that age, <z:hpo ids='HP_0003073'>hypoalbuminemia</z:hpo>, use of dialysis catheters, and IgA β-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies were independent risk factors for <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, IgA antibodies to β-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I are detrimental to the clinical outcome of hemodialysis patients </plain></SENT>
</text></document>